Revolutionizing Allogeneic Cellular Therapeutics

Cellphire Therapeutics focus is to save lives by bringing novel hemostatic products to patients most in need. Our initial product candidates have substantial advantages compared to the current standard of care, liquid stored platelets, which are subject to challenges in availability (due to short shelf life of 3-5 days), efficacy and safety:

• Stabilizing human cells for extended shelf life with rapid restoration, easy preparation and use
• Pooling cells from many donors ensuring consistent quality, safety, and scalable production
• Formulating cell therapies to achieve a desired biological outcome

‍Cellphire currently has two differentiated products in Phase 2 clinical studies, our freeze-dried platelet-derived hemostat "FPH" (Thrombosomes®), and our Cryopreserved Platelets "CPP".